De-regulated FGF receptors as therapeutic targets in cancer.
about
Role and expression of FRS2 and FRS3 in prostate cancerMetabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?Targeting RTK Signaling Pathways in CancerThe minority report: targeting the rare oncogenes in NSCLCGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsFibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesisFGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasisE7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasionFibroblast growth factor receptors in breast cancer.Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation.Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells.Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10Fibroblast Growth Factor (FGF-2) and Its Receptors FGFR-2 and FGFR-3 May Be Putative Biomarkers of Malignant Transformation of Potentially Malignant Oral Lesions into Oral Squamous Cell Carcinoma.Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.The role of human papillomavirus type 16 E6/E7 oncoproteins in cervical epithelial-mesenchymal transition and carcinogenesis.Synergistic interaction between the fibroblast growth factor and bone morphogenetic protein signaling pathways in lens cells.Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor.Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase InhibitorsDesign and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumorsAdhesion molecule signalling: not always a sticky business.Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.Fibroblast growth factors and their receptors in cancer.Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.The role of tumour microenvironment in gastric cancer angiogenesis.Targeting FGF receptors in colorectal cancer: from bench side to bed side.Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells.Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expressionFibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.A novel FGF2 antagonist peptide P8 with potent antiproliferation activity.Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling.PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
P2860
Q21261288-CCCB74E0-343C-471F-87C6-57D0F0009AA3Q26769611-0BE8BD89-1846-4C3B-B48F-D490F15E03CAQ26781278-8B507EA1-20EE-4F1C-8FA4-11A2E5239826Q26851636-DF552C86-9A84-4D7F-9352-1B50B6F21A3FQ26998790-56BC4C32-D923-487C-B129-EB4B65B397D8Q27852581-0B88BFAC-5E7D-46A0-A5A7-CB33F0C308DCQ28544931-D30AAFB3-0852-4F9D-8B25-6917B011D840Q33597813-0980F90F-9402-4086-AEDE-FAC585148555Q33751398-D7ACE1AF-9776-4AF8-A0FB-F8DE9BCD432EQ33757125-C4C0D7B9-F18F-4216-BA2E-CC1A33A28612Q33968953-7A7B19AE-98A1-412A-8D13-ACA0AEB700CFQ34556066-F6C5C753-A6A8-43E7-973B-0FC42137E4A4Q34658030-DA888D08-4CC2-43D4-8057-52DFBA075F2BQ35021476-D19FED2B-0A81-4794-A861-5FCBF8211F1FQ35169068-5BD0A5AB-D7A2-4015-9CB4-3E060FDF1813Q35608687-804BA8FB-F3EA-4AE4-B884-1ECF573EAEC8Q35806543-59AB3DD4-FB2A-4637-B2D2-D18CD0850344Q35881055-A9CF3E06-685C-4595-8166-D17B5D1D51EBQ35995375-0A3D81E9-65EC-4FEA-B6B1-3D4DF9FD6DA7Q36063693-F3AF499D-C0AD-453E-8505-6233ECDA5F35Q36129968-999644D0-B53B-4E51-9038-C6A2643F42D4Q36249025-4F37F943-2B20-48C2-B393-C4434B546419Q36762385-5A5BEA2D-D463-4325-8171-80BB7AA6AECAQ36996290-1E395D6B-E79A-4BB8-8658-0E27845D1141Q37175328-BFB49DA1-E94A-40AB-BE5D-DE3E4C8202BAQ37311579-F0B1C55A-A4A3-4F60-8027-1E561D00DB55Q37846527-4041C12B-10E8-477E-B143-066F499E0CD5Q37849781-9AA546B5-7EB8-4436-A421-0F5BA686C86CQ37895306-5D2334A3-6211-4B12-BB8E-4F74F6F5F25DQ37968256-CBAF335B-E4D0-4600-80FA-44D4C2F81398Q38214511-D44CFA84-715B-4975-A772-AED7B67321A4Q38344860-D1FBCC38-E8C2-4A9F-8CC1-E6A154FE2C7EQ38465837-648DD093-B651-4FBB-B570-1C73D71BCB0FQ38832513-63C36950-0D53-4210-ABCF-E3BC10BD8ABEQ38861579-3DB60AD1-BD9C-46BB-9184-65D4FB1DB983Q38922850-807274A9-01EA-4653-8BFE-B936226D8074Q38923517-70AE3CC5-E8DA-4D1C-9EB8-83F0CD411D35Q38971706-8A47F14E-14CA-48AD-894B-0FF76C4A6389Q39005693-703FC580-3BB6-4763-B466-644BDC7D8F5FQ39152151-9E926287-3D3C-4EB0-B851-72D49697D762
P2860
De-regulated FGF receptors as therapeutic targets in cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
De-regulated FGF receptors as therapeutic targets in cancer.
@en
De-regulated FGF receptors as therapeutic targets in cancer.
@nl
type
label
De-regulated FGF receptors as therapeutic targets in cancer.
@en
De-regulated FGF receptors as therapeutic targets in cancer.
@nl
prefLabel
De-regulated FGF receptors as therapeutic targets in cancer.
@en
De-regulated FGF receptors as therapeutic targets in cancer.
@nl
P1476
De-regulated FGF receptors as therapeutic targets in cancer.
@en
P2093
Simon J Cook
Victoria Knights
P304
P356
10.1016/J.PHARMTHERA.2009.10.001
P577
2009-10-27T00:00:00Z